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Abstract
Escherichia coli G3/10 is a component of the probiotic drug Symbioflor 2. In an in vitro assay with human intestinal epithelial
cells, E. coli G3/10 is capable of suppressing adherence of enteropathogenic E. coli E2348/69. In this study, we demonstrate
that a completely novel class II microcin, produced by probiotic E. coli G3/10, is responsible for this behavior. We named this
antibacterial peptide microcin S (MccS). Microcin S is coded on a 50.6 kb megaplasmid of E. coli G3/10, which we have
completely sequenced and annotated. The microcin S operon is about 4.7 kb in size and is comprised of four genes.
Subcloning of the genes and gene fragments followed by gene expression experiments enabled us to functionally
characterize all members of this operon, and to clearly identify the nucleotide sequences encoding the microcin itself
(mcsS), its transport apparatus and the gene mcsI conferring self immunity against microcin S. Overexpression of cloned
mcsI antagonizes MccS activity, thus protecting indicator strain E. coli E2348/69 in the in vitro adherence assay. Moreover,
growth of E. coli transformed with a plasmid containing mcsS under control of an araC PBAD activator-promoter is inhibited
upon mcsS induction. Our data provide further mechanistic insight into the probiotic behavior of E. coli G3/10.
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Introduction
Microcins are ribosomally synthesized antimicrobial peptides
with a low molecular mass. Produced by enterobacteria, mostly
Escherichia coli, microcin synthesis is sharply activated under stress
conditions such as limitation of nutrients [1–4]. Microcins exert
potent antibacterial activity against closely related species, which
offers a highly competitive advantage in the intestinal microflora
[5]. Microcin-producers are resistant to the microcin they
produce, which is mediated by at least one resistance-conferring
gene located within one gene cluster. Most of the 14 known
microcins are plasmid-encoded [5–10], but chromosomally-
encoded antibacterial peptides have also been described [11].
The probiotic strain E. coli Nissle 1917 (EcN) is known to produce
microcins M and H47 [12]. In this study we show that probiotic E.
coli G3/10 produces a novel microcin, that we named microcin S
(MccS). E. coli G3/10 is one of six E. coli genomotypes present in
the probiotic drug Symbioflor 2 (DSM17252). the product has
been successfully used for the treatment of functional gastrointes-
tinal disorders, in particular irritable bowel syndrome in adults and
children [13,14]. Probiotics are defined as living microorganisms,
which upon ingestion in certain numbers, exert health benefits
beyond inherent basic nutrition [15]. The mechanisms that enable
a strain to serve as a probiotic are poorly understood.
Nevertheless, the antimicrobial activity of microcins could
positively influence the stability of the intestinal microflora. Given
its extensive clinical safety record, a microcin-producing strain
containing no virulence factors can clearly fulfill the definition of a
probiotic. In contrast to enterobacterial microcins, food-borne
lactic acid bacteria produce lanthionine-containing peptide
antibiotics. The so-called lantibiotics of gram-positive bacteria
are already used for food preservation [16]. The use as an
antitumor agent [17] or as an alternative to classical antibiotics in
infectious diseases [18,19] are two further applications where
bacteriocins may provide therapeutic alternatives in the future.
The worldwide emergence of pathogens resistant to antibiotics has
led to an ever-increasing demand of new antibacterial agents.
Enterobacterial microcins could offer exciting new possibilities for
prophylaxis and treatment of bacterial infections. Here we present
the identification and functional characterization of microcin S, a
completely novel plasmid encoded bacteriocin produced by
probiotic E. coli G3/10. Microcin S is able to inhibit the adherence
of enteropathogenic E. coli (EPEC) strain E2348/69 to intestinal
epithelial cells in an in vitro adherence assay and growth of E. coli is
hampered by L-arabinose induced recombinant expression of
MccS.
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Evaluation of the In vitro Adherence Assay
Bacterial adhesion is a crucial first step of many infectious
diseases. Therefore, a test system quantifying adherence inhibition
of enteropathogens to human intestinal epithelial cells is a suitable
model system to evaluate this beneficial effect to the host. Initially,
we used enteropathogenic E. coli strain E2348/69 [20] to
investigate adherence efficiency to human intestinal epithelial cells
(LOVO or CACO-2) in response to a pre-incubation with
different probiotic or non-probiotic E. coli isolates. We demon-
strated that EcN significantly inhibits EPEC adherence (Fig. 1A),
which is consistent with the results of Kleta et al. [21] who used a
similar assay with porcine intestinal IPEC-J2 cells. Since EcN
produces two different microcins M and H47 [12], we assumed
that the observed effect resulted from those antibacterial peptides,
which can inhibit bacterial growth and kill target bacteria. Indeed,
we were able to show that an EcN deletion strain (EcNDS20),
Figure 1. Adherence efficiency of EPEC E2348/69 to human intestinal epithelial cells after pre-incubation with E. coli Nissle 1917
(EcN) and EcN deletion strains (EcNDS) (A); E. coli G1/2, E. coli G3/10, E. coli G4/9, E. coli G5, E. coli G6/7 and E. coli G8, the components
of Symbioflor 2 (DSM17252) (B); E. coli strains MDS42 and G4/9 wild-type and appropriate mutants (C). Confluent monolayers of CACO-
2 or LOVO cells were pre-incubated with bacterial test strains at an MOI of 100:1 E. coli to host cells. After two hours of incubation, cells were washed
and infected with EPEC E2348/69 using an MOI of 100:1 EPEC to host cells. Adherence efficiency in % is expressed as adherence of EPEC relative to the
adherence without any pre-incubation (negative control), which is set at 100%. Pre-incubation of human intestinal epithelial cells with EcN
significantly reduces adherence efficiency of EPEC E2348/69, comparable to the mutant strains EcNDS24 and EcNDS23 which carry single genomic
deletions of either microcin H47 precursor (mchB; EcNDS24) or microcin M precursor (mcmA; EcNDS23). However, this phenomenon cannot be
observed, when double microcin mutant EcNDS20 is used (A). The adherence efficiency of EPEC E2348/69 is also significantly reduced in the presence
of microcin S, either expressed by E. coli G3/10 wild-type (B) or by E. coli strains MDS42 and G4/9, transformed with plasmids pSYM1-ST76An (mcsS,
mcsI, mcsA, mcsB), pAZ6 (mcsS, mcsI, mcsA, mcsB) or pAZ9 (mcsS) (C). With all further plasmids, pAZ8 (mcsI, mcsA, mcsB), pAZ10 (ORF1), pAZ11 (ORF2)
and pAZ12 (mcsS193–363), the indicator strains E. coli MDS42 and G4/9 did not inhibit adherence of EPEC E2348/69 to intestinal epithelial cells (C). Data
are the mean6SD of at least three separate experiments in duplicate wells. * p#0.01 compared to negative controls or wild-type strains.
doi:10.1371/journal.pone.0033351.g001
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EPEC adhesion (Fig. 1A), whereas deletion of only one microcin
(EcNDS23 and EcNDS24) resulted in wild-type behavior (Fig. 1A).
Therefore, the in vitro adherence assay used here also provides a
suitable test environment for detecting bactericidal activity of a
given strain specifically directed against the used adherent strain.
Identification of the Microcin S-Encoding Gene Cluster in
E. coli G3/10
The EPEC in vitro adherence assay was then repeated with all
genomotypes of the probiotic drug Symbioflor 2, which are E. coli
G1/2, G3/10, G4/9, G5, G6/7 and G8. Surprisingly, we could
show that E. coli G3/10 also significantly inhibited EPEC
adherence efficiency (Fig. 1B) indicating a bactericidal activity of
that strain. The genome of E. coli G3/10 was sequenced in our
laboratory (unpublished data). However, neither during manual
editing of the automatically annotated sequence nor with a
BLAST analysis, could any coding sequences of a known microcin
be identified within the genome of E. coli G3/10. Microcins are
often encoded by plasmids [5]. E. coli G3/10 contains a large
conjugative plasmid pSYM1 (Fig. 2), having a size of 50.6 kb. The
plasmid is 99% identical to plasmid pMAS2027 of uropathogenic
E. coli MS2027 [22]. However, it additionally contains a 10 kb
insertion fragment, which carries only uncharacterized and
unnamed genes. To identify the origin of E. coli G3/10s
bactericidal action we first tried to cure the strain from its
megaplasmid pSYM1. However, while using several common
curing procedures such as treatment with mitomycin C or heat, we
failed to remove pSYM1 from E. coli G3/10. Therefore, the
plasmid was transferred to E. coli G4/9 by conjugation. To allow
screening of conjugants, we first integrated an ampicillin resistance
cassette into pSYM1 resulting in pSYM1-ST76An (Table 1). E. coli
G4/9 transformed with pSYM1-ST76An was able to inhibit
EPEC adherence significantly (Fig. 1C). It logically followed that
plasmid pSYM1 carries genes responsible for the observed effect.
Then, we cloned a 4.7 kb subfragment of plasmid pSYM1 into
pBR322, resulting in plasmid pAZ6 (Table 1), which was
subsequently transformed into E. coli G4/9. We demonstrated
that pAZ6 enables E. coli G4/9 to inhibit EPEC adherence
efficiency significantly (Fig. 1C), indicating that the 4.7 kb
fragment of pSYM1 (Fig. 3) is responsible for the EPEC adherence
inhibition effect of E. coli G3/10. BLAST analysis of automatically
annotated open reading frames (ORFs) in this segment of pSYM1
revealed small homologies to characterized proteins or protein
families belonging to microcin-encoding operons. Nevertheless,
the microcin itself remained undetected. For this reason, we
cloned three genes, named mcsI, mcsA and mcsB in the following,
Figure 2. Circular diagram of megaplasmid pSYM1. The outer circle indicates (to scale) the genetic organization of ORFs within the plasmid.
The direction of transcription of each ORF is indicated. The middle circle indicates the GC content, and the inner circle indicates the GC skew. The
10 kb region of pSYM1 that is different from pMAS2027 is marked. The image was constructed using cgview [41]. CDS=coding sequences.
doi:10.1371/journal.pone.0033351.g002
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this operon (Fig. 3), which were candidate microcin-encoding
genes, were cloned into pACYC184 and subcloned into E. coli
G4/9 pAZ8. With this strategy we successfully managed a
sequential plasmid-based identification and characterization of
potential microcin-coding regions together with the respective
microcin-helper proteins. Only E. coli G4/9, containing plasmids
pAZ8 and pAZ9 (Table 1) together, significantly inhibited EPEC
adherence, whereas E. coli G4/9 pAZ8 affected EPEC adherence
similar to that of E. coli G4/9 wild-type (Fig. 1C). We therefore
concluded that the small gene cloned into pAZ9, which we termed
mcsS, encodes a novel E. coli microcin, named microcin S in the
following. Truncated mcsS (pAZ12; Table 1) resulting from an
alternative ORF did not show microcin activity in the in vitro
adherence assay (Fig. 1C).
Microcin S Immunity
Class II microcins are characterized by a dedicated self-
immunity protein. Gene mcsI adjacent to mcsS shows homology to
the CAAX amino terminal protease family potentially involved
in microcin self-immunity. No signal sequence or transmembrane
helices are predicted. We transformed mcsI into EPEC strain
E2348/69 using either pAZ8 (mcsI, mcsA, mcsB), pAZ13 (mcsI )o r
pAZ14 (mcsI, truncated). We could show that the EPEC strain
carrying the complete mcsI gene (pAZ8 or pAZ13) is resistant to
microcin S-producing E. coli G3/10 or E. coli G4/9 pAZ6 in the
in vitro adherence assay. Truncated mcsI (pAZ14) was not able to
confer microcin S resistance. Therefore we identified gene mscI,
which encodes a 216 amino acid protein, as responsible for
microcin S self-immunity. Additionally, we demonstrated that
mcsI is not effective against EcN microcins M and H47 (Fig. 4).
Investigation of Microcin S Activity in E. coli MDS42
In order to directly demonstrate microcin S activity against a
susceptible E. coli strain, mcsS was cloned into pGS1 resulting in the
plasmid pAZ15 (Table 1). In this construct, mcsS expression is
controlled by an araC PBAD activator-promoter, rendering
microcin S expression inducible by L-arabinose. When E coli
MDS42 [23] growing in liquid culture after being transformed
with pAZ15 was treated with 0.2% v/v L-arabinose at the
beginning of the logarithmic phase after 1.5 h, A600 remained
almost stable around 0.3 while absorbance of control cultures
increased constantly (Fig. 5A). Counts of colony forming units
(CFU) taken at various time points during this experiment revealed
a sharp drop in the number of viable bacteria in the L-arabinose
induced culture of E. coli MDS42+pAZ15 while CFU of the other
cultures rose to a maximum of 1.4 610
9/ ml (Fig. 5B).
Presence of Microcin S Gene in Enterobacteriaceae
The sequences of mcsS and mcsI were listed very recently
(04.09.2011) as new entries in the NCBI database, being part of
the 54 kb megaplasmid pMO17_54 (accession # HE578057) of
Shigella sp. MO17. The proteins derived from these coding
sequences, termed pMO17_54_21 and pMO17_54_23, were
described as hypothetical proteins and no function was assigned
to them. Nevertheless, a complete MccS operon is not listed in
NCBI (as of 21.10.2011). A further 38 E. coli, two Shigella and two
Salmonella strains were screened for mcsS using a multiplex PCR
protocol. We were unable to detect the mcsS gene in any of the 42
human and veterinary isolates or the laboratory strains tested
(Fig. 6).
Discussion
Microcins are small ribosomally synthesized peptides produced
by enterobacteria. We could show that E. coli G3/10, an E. coli
genomotype of Symbioflor 2 (DSM17252), encodes and produces
a completely novel class II microcin, named microcin S. The term
microcin was introduced to distinguish this class of antibacterial
peptides with a size ,10 kDa from colicins with a higher
molecular mass [24]. Genome sequencing of E. coli G3/10 enabled
us to indentify the gene mcsS, located on plasmid pSYM1,
encoding the 120 amino acid (aa) microcin S precursor peptide. It
has a calculated molecular weight of 11.67 kDa and is therefore
the largest of all currently known microcins. Using the Pfam
database [25] microcin S can be classified as a class II bacteriocin
with a double-glycine leader peptide. Indeed, its amino acid
sequence reveals a glycine-rich peptide with a double-glycine
cleavage site and cysteines probably involved in formation of a
disulfide bond (Fig. 3). These characteristics, together with the
organization of the microcin gene cluster (Fig. 3), indicate MccS to
be a member of the class IIa microcins. The current classification
follows a discussion of Duquesne et al. [26] and Rebuffat [27].
MccV (formerly colicin V), MccL and Mcc24 are three members
assigned to the microcin class IIa. All are composed of four
plasmid-borne genes, mostly harbored by large conjugative low-
copy-number plasmids [7,10]. The genes for MccV and MccL,
cvaC and mclC, encode 103 and 105 aa precursors, which also
constitute higher-molecular mass microcins. Both peptides form
disulfide bonds [28,29]. Class IIa microcins have leader peptides
whose cleavage results in the mature biologically active peptide.
Furthermore, they are not subject to post-translational modifica-
tion. Gene clusters of all class IIa microcins consist of four genes
organized in one or two transcription units: the gene encoding the
microcin precursor, a self-immunity protein, an accessory protein
involved in the secretion of the microcin, and an ATP-binding
cassette (ABC)-transporter (for reviews see [26,30]). The self-
immunity genes code for small peptides that protect the producing
strain from its own microcin. Here we can show that gene mcsI
cloned into EPEC E2348/69 confers immunity to MccS. Gene
Table 1. Plasmids used in this study.
Plasmid Resistance
Relevant
genotype Origin
pSYM1 None mcsS, mcsI, mcsA,
mcsB
This work
pST76–A Amp
r ori
TS (30uC) [43]
pSYM1–ST76An Amp
r mcsS, mcsI, mcsA,
mcsB
This work
pAZ6 Amp
r mcsS, mcsI, mcsA,
mcsB
This work
pAZ8 Amp
r mcsI, mcsA, mcsB This work
pAZ9 Cm
r mcsS This work
pAZ10 Cm
r ORF1 This work
pAZ11 Cm
r ORF2 This work
pAZ12 Cm
r mcsS193–363 This work
pAZ13 Amp
r mcsI This work
pAZ14 Amp
r mcsI361–651 This work
pGS1 Amp
r PBAD This work
pAZ15 Amp
r PBAD, mcsS This work
Amp
r=ampicillin resistance; Cm
r=chloramphenicol resistance; ORF=open
reading frame; PBAD=araC PBAD activator-promoter.
doi:10.1371/journal.pone.0033351.t001
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protease protein family. The two genes comprising the MccS
export system are mcsA and mcsB (Fig. 3). Gene mcsA is a member
of the E. coli HlyD family and shows little homology to the colicin
secretion protein CvaA. Gene mcsB encodes an ABC-transporter
consisting of a transmembrane domain, an ATP-binding domain
and a peptidase domain [25]. The nucleotide lengths of mcsA and
mcsB from the MccS operon, 1254 bp and 2178 bp respectively,
are comparable to export genes of the other microcins MccV (cvaA,
1242 bp; cvaB, 2097 bp), MccL (mclA, 1242 bp; mclB, 2097 bp) and
Mcc24 (mtfA, 1245 bp; mtfB, 2124 bp) [26]. The sensitivity of
microorganisms to microcins can generally be shown by a
standard agar diffusion test, for example with the microcin-
producing strain spotted onto an agar plate and an indicator strain
inoculated into a soft agar overlay [12]. However, E. coli G3/10
does not produce real inhibition zones in agar diffusion tests (data
not shown). This phenomenon can possibly be explained by the
widely unknown conditions for effective MccS expression.
Motivated by the fact that synthesis of MccV is repressed by
excess iron [31], we added the iron chelator Desferal to the solid
media growing E. coli G3/10 in the diffusion test. However,
microcin production on agar plates could still not be shown. We
Figure 3. The MccS gene cluster. The upper panel shows the amino acid sequence of the microcin S precursor. A probable leader peptide is
underlined. Asterisks indicate cysteines possibly involved in the formation of a disulfide bond typical for class II microcins. The microcin S gene cluster
on megaplasmid pSYM1 (lower panel) consists of the four clustered genes mcsS, mcsI, mcsA and mcsB. ORF1 and ORF2 revealed no bactericidal
activity.
doi:10.1371/journal.pone.0033351.g003
Figure 4. Adherence efficiency of wild-type and mutant strains of EPEC E2348/69 to human intestinal epithelial cells after pre-
incubation with different microcin positive and negative E. coli strains. Confluent monolayers of CACO-2 or LOVO cells were pre-incubated
with bacterial test strains EcN, E. coli G3/10, microcin-negative E. coli G4/9 wild-type or microcin S expressing E. coli G4/9 pAZ6 at an MOI of 100:1 E.
coli to host cells. After two hours of incubation, cells were washed and infected with EPEC E2348/69 using an MOI of 100:1 EPEC to host cells.
Adherence efficiency in % is expressed as adherence of EPEC relative to the adherence without any pre-incubation (negative control), which is set at
100%. In EPEC E2348/69 plasmids pAZ8 (mcsI, mcsA, mcsB) and pAZ13 (mcsI) containing full-length gene mcsI confer immunity to mcsS expressing
strains E. coli G3/10 and E. coli G4/9 pAZ6. However, EPEC indicator strain transformed with pAZ14 carrying truncated mcsI361-651 is not resistant to
microcin S. None of the plasmids used procures immunity against EcN microcins H47 and M. Data are the mean6SD of at least three separate
experiments in duplicate wells. * p # 0.01, ** p # 0.05.
doi:10.1371/journal.pone.0033351.g004
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be involved in the regulation of microcin S expression. Because the
adherence assay provides only indirect proof of the antibacterial
activity of MccS-producing E. coli strains and the above mentioned
agar diffusion test did not work properly with microcin S, we
decided to subclone mcsS under the control of an araC PBAD
Figure 5. Growth curve of E. coli MDS42 with pAZ15 or pGS1 showing A600 (A) and colony count of viable cells (B). pAZ15 is a vector
containing mcsS under control of the L-arabinose-induced araC PBAD activator-promoter. Induction with L-arabinose of the respective cultures, as
indicated in the legend to panel A and B, was carried out after 90 minutes. pGS1 is the empty vector with the araC PBAD activator-promoter. E. coli
MDS42 with pAZ15 shows a significant reduction of its A600 as well as of its colony counts after induction with L-arabinose (red squares) compared
to growth without induction (green triangles) and also with the vector devoid of mcsS (pGS1, blue rhombi). Data are the mean6SD of three
independent experiments.
doi:10.1371/journal.pone.0033351.g005
Figure 6. Multiplex PCR to screen for presence of mcsS using recA as inhibition control. The tested strains are common laboratory strains,
human clinical isolates and veterinary isolates of different origin. mcsS could not be detected in any of the tested strains while the amplified inhibition
control indicated that all PCR reactions were truly negative.
doi:10.1371/journal.pone.0033351.g006
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with L-arabinose in E. coli MDS42 growing in liquid culture,
viable counts dropped by several logs, clearly indicating a direct
toxic activity of MccS against a susceptible E. coli strain. MccS
from E. coli G3/10 has the great advantage that the microcin does
not necessarily have to be purified from the strain. Since E. coli
Table 2. Bacterial strains used in this study.
Strain Relevant genotype Origin
E. coli Nissle 1917 DSM6601 [42] Wild-type Mutaflor, Ardeypharm
EcNDS20 ?mcmA, ?mchB This work
EcNDS23 ?mcmA This work
EcNDS24 ?mchB This work
E. coli G1/2 Wild-type Symbioflor 2
a, SymbioPharm
E. coli G3/10 Wild-type Symbioflor 2
a, SymbioPharm
E. coli G4/9 Wild-type Symbioflor 2
a, SymbioPharm
E. coli G5 Wild-type Symbioflor 2
a, SymbioPharm
E. coli G6/7 -type Wild Symbioflor 2
a, SymbioPharm
E. coli G8 Wild-type Symbioflor 2
a, SymbioPharm
E. coli MDS42 [23] E. coli K-12 multiple deletion strain F. Blattner, University of Wisconsin - Madison, USA
EPEC E2348/69 [20] Amp
r (pUC19), Kana
r (pUC4k) or Cm
r
(pACYC184)
Human isolate
aDSM17252; EcNDS=E. coli Nissle 1917 deletion strain; Amp
r=ampicillin resistance; Kana
r=kanamycin resistance; Cm
r=chloramphenicol resistance.
doi:10.1371/journal.pone.0033351.t002
Table 3. Oligonucleotide primers used in this study.
Oligonucleotide Sequence (59R 39) Function
mcm-H1 cttaaagcgttacataggcaccattatcatataatgaagcaccgattgtgtaggctggagctgcttc EcN deletion primer
mcm-H2 gaatttttacttcttcacaaatcttatagcgaaggtgttgaaatggtccatatgaatatcctcctta EcN deletion primer
mch-H1 atcaacgactgtaaatcatatcttcatcagtaaagtgttgaacgattgtgtaggctggagctgcttc EcN deletion primer
mch-H2 ggtcaggctggaaaaacggaagttaaatatgatggagtttatatggtccatatgaatatcctcctta EcN deletion primer
mcm_for cgttcggaggagcctaac EcN deletion primer/sequencing
mcm_rev gattcatgggattcgaagg EcN deletion primer/sequencing
Contig49_for cagctggatatcctgcgcg pSYM1 sequencing primer
Contig49_rev ggttgcccggcatccaacg pSYM1 sequencing primer
pSYM1-SalIHF tcaattgtgtcgactcaattactcttgtgag pAZ6/pAZ8 cloning primer
pSYM1-NheI catgtaatagtgctagcatgttaaaatttataag pAZ6 cloning primer
pSYM1-NheIac caaaaataatagctagcaagtgatgttttgtaatg pAZ8, pAZ12 cloning primer
ac-EcoRI ctcgaattcatccattacaaaacatcac pAZ9 cloning primer
ac-PstI ctggctgcagtaattgttcaggaagtaacg pAZ9 cloning primer
pSYM1_44–EcoRI taggaattcagaggaactattggtggg pAZ10 cloning primer
pSYM1_44–PstI ctccgctgcagacttacttatcgactacaggtaccac pAZ10 cloning primer
ab-EcoRI gttagaattcataagagggatttttatgtcaaatatc pAZ11 cloning primer
ab-PstI gttgatactgcagcttatcgactacaggtaccacc pAZ11 cloning primer
pAZ9-HindIII cccaagcttagttaaatgtgctaatgctgtc pAZ12 cloning primer
pAZ9-SalI ggcatcggtcgacgcaac pAZ12 cloning primer
pSYM1_43–NheI cattgctagccatcacagataaactggataac pAZ14 cloning primer
pSYM1_43–SalI ccctgagtcgactcatggttataaaatattttg pAZ13, pAZ14 cloning primer
recA–ff atggctatcgacgaaaacaaac Multiplex PCR inhibition control
recA–rev ttaaaaatcttcgttagtttctgc Multiplex PCR inhibition control
mcsS–ff atgtcaaatatcagagaattgag mcsS PCR screening primer
mcsS–rev ttatcgactacaggtaccacc mcsS PCR screening primer
Oligonucleotides were synthesized by Biomers, Ulm, Germany.
doi:10.1371/journal.pone.0033351.t003
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treatment of gastrointestinal disorders, MccS is very much likely to
also be expressed effectively in vivo, rendering this beneficial
microorganism a promising biological drug with prophylactic
capacities against enteric pathogens such as Salmonella, Shigella
or diarrheagenic E. coli.
Materials and Methods
Bacterial Strains and Growth Conditions
Bacterial strains used in this work are listed in table 2. Bacteria
were grown in Luria Bertani (LB) medium or on LB agar plates
(BectonDickinson,BD,Heidelberg,Germany).Culturemediawere
supplemented with ampicillin (100 mgm l
–1), chloramphenicol
(25 mgm l
–1), kanamycin (50 mgm l
–1), tetracyclin (12.5 mgm l
–1)o r
streptomycin (30 mgm l
–1) as required. Antibiotics were purchased
from AppliChem, Darmstadt, Germany.
Construction of EcN Microcin Deletion Mutants
EcN mutants negative for chromosomally encoded microcins M
and H47 (mcmA, mchB) were constructed with a PCR-based one-
step inactivation method [32,33]. Deletions were controlled by
PCR using primer pairs outlined in table 3 as well as automated
DNA sequencing based on dideoxy chain termination method
[34], using an ABI 3100 sequencing instrument (Life Technolo-
gies, Darmstadt, Germany).
Construction of Plasmids Used for Functional
Characterization of the Microcin S Operon
The targeted sequence was amplified by PCR using oligonu-
cleotides with 59 restriction sites (Table 3). Due to their
proofreading capacity, PCR was performed with Phusion High-
Fidelity DNA-Polymerase (Thermo Fisher Scientific/Finnzymes,
Vantaa, Finland) according to the recommended protocol.
Following purification of PCR products with columns containing
silica membranes (Qiagen, Hilden, Germany), fragments were
digested with the respective restriction enzymes (New England
Biolabs, NEB, Frankfurt (Main), Germany) and ligated into an
appropriate vector using T4 DNA-Ligase (NEB). Ligated DNA
constructs were then transformed to competent bacteria by
electroporation (2.5 kV; 400 V;2 5mFD) using a Bio-Rad Gene
Pulser II and Pulse Controller Plus (Munich, Germany). Clones
were selected on LB agar plates containing the appropriate
antibiotic and were confirmed by PCR, DNA sequencing and by
restriction digest using the respective enzymes.
Conjugation Experiments
The conjugative plasmid pSYM1 allows the transfer to a
recipient strain. pSYM1 was mobilized from E. coli G3/10 into E.
coli G4/9 following a protocol published by Miller et al. [35] with
slight modifications. E. coli G4/9 was chosen as the recipient strain
because it is closely related to E. coli G3/10 and harbors only one
natural plasmid (unpublished data). Since donor and recipient
require dissimilar antibiotic resistance, suicide vector pST76-A,
containing an ampicillin resistance cassette and a temperature-
sensitive origin of replication, was integrated into pSYM1 by
homologous recombination, resulting in pSYM1-ST76An. Then,
recipient strain E. coli G4/9 was transformed with pACYC184
conferring it with chloramphenicol resistance. Donor E. coli G3/10
and recipient E. coli G4/9 were grown in LB medium to an
absorbance of A600 , 0.5 to 1, each containing the appropriate
antibiotic. Cells were pelleted in a bench top centrifuge at 5000 g
for 10 min, washed twice with phosphate buffered saline (PBS) and
resuspended in LB medium. Donor and recipient were mixed 2:1,
pelleted and resuspended in a small volume of LB medium
(,100 ml). The cell suspension was plated on blood agar (BD) and
incubated overnight at 37uC. Bacteria were resuspended in 1 ml
LB medium, diluted in PBS and plated on MacConkey agar (BD)
containing 25 mgm l
-1 chloramphenicol and 100 mgm l
-1 ampicillin
(AppliChem). The resulting clones were confirmed by PCR.
Sequencing and Annotation of pSYM1
Plasmid pSYM1 was discovered as one of six wild-type plasmids
in E. coli strain G3/10. The genome of the strain was obtained by
pyrosequencing with a 454 GS-FLX System (Roche, Basel,
Switzerland) (unpublished data). About ninety-five percent of the
plasmid sequence was amassed during genome sequencing and
assembly. Then, primers for an outwardly directed primer walking
strategy were designed (Table 3) until a completely closed plasmid
sequence was obtained. Annotation was performed automatically
at CeBiTec followed by manual revision using GenDB 2.4
software [36]. BLASTn and BLASTp searches were done using
the National Center for Biotechnology Information (NCBI)
website [37].
LOVO and CACO-2 Cell Culture Conditions
The human intestinal epithelial cell lines LOVO [38] and
CACO-2 [39] , purchased from DSMZ [40], were grown in
RPMI-1640 cell culture medium (Biochrom, Berlin, Germany)
supplemented with 10% FCS (Biochrom) and maintained in an
atmosphere of 5% CO2 at 37uC. Cells reached confluency after 3–
4 days and were used consistently within 3–4 days from seeding.
Cell cultures were tested routinely and found to be free from
mycoplasma contamination.
In vitro Adherence Assay
An in vitro adherence assay was performed according to a
modified protocol from Kleta et al. [21]. Briefly, human
intestinal epithelial LOVO or CACO-2 cells were seeded in
24-well plates and grown to confluency. Bacterial strains to be
tested were grown in LB broth to an absorbance of A600 , 0.6,
whereas the adherent enteropathogenic E. coli strain E2348/69
was grown to A600 , 1, each supplemented with the appropriate
antibiotic. One ml of each bacterial strain was pelleted, washed
with PBS and resuspended in cell culture medium. LOVO and
CACO-2 cells were infected with the bacteria to be tested at a
multiplicity of infection (MOI) of 100:1 E. coli to host cells. After
an incubation period of two hours at 37uC and 5% CO2 bacteria
were washed away with PBS for three times and host cells were
infected with EPEC. Bacteria were allowed to adhere for six
hours in total (37uC, 5% CO2), while the cell culture medium
was replaced after three hours of incubation. Cells were washed
with PBS and lysed with 0.01% Triton-X-100 in PBS (Sigma-
Aldrich, Munich, Germany). The number of adherent EPEC was
determined by plating serial dilutions on LB agar plates
containing the appropriate antibiotic. Adherence efficiency in
percentage is expressed as adherence of EPEC relative to the
adherence without any pre-incubation (negative control), which is
set at 100%. All strains were tested in at least three independent
experiments.
Screening of mcsS Presence in Enterobacteria
Gene mcsS encoding microcin S was amplified by a multiplex
PCR protocol from culture material, using recA as an inhibition
control. Oligonucleotides were used as indicated in table 3. E. coli
G3/10 served as positive control. Thirty-eight different E. coli, two
Shigella and two Salmonella strains were screened. To our
New Microcin Produced by Probiotic E. coli
PLoS ONE | www.plosone.org 8 March 2012 | Volume 7 | Issue 3 | e33351knowledge, none of the isolates tested has been sequenced. Strains
are common lab strains as well as isolates of human or animal
origin as indicated in figure 6.
Statistical Analysis
Data are expressed as mean6SD. Student’s t-test was used to
determine the statistical significance. p#0.05 was considered
statistically significant.
Nucleotide Sequence Accession Number of pSYM1
The pSYM1 plasmid sequence has been deposited in the
GenBank sequence database with the accession number
JN887338.
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